Toxicities of organs at risk in the Mediastinal and Hilar regions following stereotactic body radiotherapy for centrally located lung tumors

Shuichi Nishimura, Atsuya Takeda, Naoko Sanuki, Satoshi Ishikura, Yohei Oku, Yousuke Aoki, Etsuo Kunieda, Naoyuki Shigematsu

Research output: Contribution to journalArticle

33 Citations (Scopus)


INTRODUCTION: We investigated tolerable doses to organs at risk (OARs) in the mediastinum and pulmonary hilum following stereotactic body radiotherapy for centrally located lung tumors. METHODS: Between 2005 and 2012, 381 patients with lung tumors were treated with stereotactic body radiotherapy of 40 to 60 Gy in five fractions. From among these patients, we extracted those who received greater than 25 Gy irradiation to OARs and analyzed dosimetric factors in relation to grade 3 to 5 toxicities. RESULTS: In total, 398 OARs in 133 patients were analyzed, with a median follow-up of 33 (range, 3-87) months. The numbers receiving greater than 25 Gy irradiation to the aorta, vena cava, pulmonary artery, pulmonary vein, bronchus, trachea, heart, and esophagus were 72, 33, 73, 60, 55, 13, 69, and 23, respectively. The corresponding median Dmax 0.5 ml were 43.8, 32.0, 32.2, 29.1, 28.4, 28.7, 41.1, and 21.7 Gy. Of these patients, two developed grade 5 and one grade 3 hemoptysis, and two had grade 3 obstructive pneumonia. Two patients with grade 5 hemoptysis received high doses at the pulmonary artery and bronchus (59.2 and 54.4 Gy, and 61.3 and 59.6 Gy, respectively). No other grade 3 to 5 toxicities occurred. CONCLUSION: Therapeutic indications and dose-intensity should be carefully determined for patients with central tumors, especially when doses to the pulmonary artery and bronchus in the pulmonary hilum exceed 50 Gy. Tolerable doses for other OARs might, however, be higher than in this study, though longer follow-up is necessary to assess this possibility.

Original languageEnglish
Pages (from-to)1370-1376
Number of pages7
JournalJournal of Thoracic Oncology
Issue number9
Publication statusPublished - 2014 Sep



  • Centrally located lung tumor
  • Dose-volume histograms
  • Organs at risk
  • Stereotactic body radiotherapy
  • Toxicities

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this